Ingredients

5-Hydroxytryptophan (5-HTP), magnesium citrate, Ginkgo biloba extract, melatonin, zinc and vitamin B.

Indications

Tinnitan® Duo from Laboratorios Salvat is a dietary supplement.

Some common disorders, such as hearing loss and tinnitus can be caused by trauma to the ear. These conditions are related to damage of the small auditory nerves which reduce blood flow and increase oxidative stress. This cascade of events disrupts functioning and causes a worsening of symptomatology. Providing neuroprotection can be of great help in minimizing the damage to the affected nerves in these conditions. In this respect, several studies (ref. 1, 2, 3, 4) describe the mechanisms of action of compounds like magnesium, Ginkgo biloba and melatonin. These compounds have  been found to have beneficial properties for People with disorders affecting the auditory nerve when taken as dietary supplements.

Tinnitan® Duo contains melatonin which reduces the time taken to fall asleep. It also contains magnesium which contributes to the normal function of the nervous system.

Tinnitan® Duo also contains 5-HTP, an aminoacid precursor of serotonin and melatonin. It also contains vitamin B5 and B6 which help to accelerate the transformation of 5-HTP into serotonin.

Presentation

Box of 60 capsules: 30 white capsules and 30 blue capsules.

Dosage

1 WHITE capsule in the morning (breakfast) and 1 BLUE capsule before bedtime.

References

1. Mahmoudian-Sani MR, Hashemzadeh-Chaleshtori M, et al. Ginkgo biloba in the treatment of tinnitus: An updated literature review. Int Tinnitus J. 2017;21(1):58-62.

2. Tziridis K, Korn S, et al. Effects of Ginkgo biloba extract EGb 761 against noise trauma-induced hearing loss and tinnitus development. Neural Plast. 2014; 2014: 427298.

3. Uluyol S, Kılıçaslan S, Yağız Ö. Relationship between serum magnesium level and subjective tinnitus. Kulak Burun Bogaz Ihtis Derg. 2016;26(4):225-7.

4. Abtahi SH, Hashemi SM, et al. Comparison of melatonin and sertraline therapies on tinnitus: A randomized clinical trial. Int J Prev Med. 2017;8:61.

Esta web usa 'cookies' propias y de terceros para ofrecerte una mejor experiencia de servicio. Al navegar o utilizar nuestros servicios, aceptas el uso que hacemos de las 'cookies'. Sim embargo, puedes cambiar la configuración de 'cookies' en cualquier momento.

VER MÁS

This web uses cookies (including some third party) to facilitate the use of our website. By browsing this web or using its services, you are accepting how we use these cookies. However, you may change the cookie configuration at any time.

READ MORE